MedPath

Fentanyl and Clonidine for Analgesia During Hypothermia in Term Asphyxiated Infants

Completed
Conditions
Asphyxia Neonatorum
Interventions
Registration Number
NCT03177980
Lead Sponsor
Region Skane
Brief Summary

A prospective pharmacokinetic (PK), pharmacodynamic (PD) and pharmacogenetic (PG) observation study, including the PK/PD/PG relationship, in fentanyl and clonidine administered for analgesia and sedation to term newborn asphyxiated infants receiving hypothermic treatment in the NICU.

Detailed Description

All patients that are admitted to the study neonatal intensive care units (NICUs) for hypothermic treatment due to perinatal asphyxia are potential study patients, and their parents will be asked for consent.

The patient will be treated according to clinical guidelines and will be included in the study if in need for fentanyl and clonidine according to clinical judgment (HIE and pain scores) and as decided by the responsible clinical doctor. The dosing and administration of the drugs will be implemented according to an algorithm based on pain scoring results.

Apart from extra blood sampling, the bedside monitoring, investigations (electroencephalography (EEG), echocardiography (ECG), ultrasound of the brain and magnetic resonance imaging, (MRI)) and follow-up (neurologic examination) are the same as for all infants receiving hypothermia according to national and international guidelines. A brief standardised pain stimulation will be performed as part of the pain and stress assessment.

In total 50 infants will be included.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
49
Inclusion Criteria
  • Term infants (≥ gw 36+0) who, according to national guidelines (6), will receive hypothermic treatment following perinatal asphyxia, and are in need for analgesic or sedative medication according to clinical judgment based on Thomsons score and ALPS-Neo.
  • Existing arterial or venous cannulas/catheters for repeated non-traumatic blood sampling
  • Informed and written parental consent.
Exclusion Criteria
  • Atrioventricular (AV)- block I-III or heart rate < 70 .
  • Serious coronary heart disease with need for postnatal surgery
  • Mean arterial blood pressure <35 mmHg despite adequate treatment.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Fentanyl and ClonidineFentanyl and clonidineInfants in need of further analgesia according to an algorithm based on pain assessment results will receive fentanyl and clonidine as the analgesic drugs.
FentanylFentanylAll infants in need of analgesia according to an algorithm based on pain assessment results will receive fentanyl as the first analgesic drug.
Primary Outcome Measures
NameTimeMethod
Pharmacokinetics (PK) of fentanyl and clonidineRepeated blood samples over a total of 4 - 7 days]

Analysed with NONMEM (Non-linear Mixed Effect Modelling) populationbased PK statistics

Neurophysiologic response; by single cortical events and their dynamics in relation to PKFrom admission to the department until 4- 72 h after reaching normothermia.]

Analyse of single cortical events and their dynamics based on burst detection and measuring features of individual bursts as well as their mass statistical behaviour over time.

Neurophysiologic response; longer term brain function in relation to PKFrom admission to the department until 4- 72 h after reaching normothermia

Assessment of longer term brain function using measures of long range correlation and brain activity cycling.

Neurophysiologic response; global brain network function in relation to PKFrom admission to the department until 4- 72 h after reaching normothermia

Assessment of global brain network function will be based on Activation Synchrony Index.

Secondary Outcome Measures
NameTimeMethod
Change in pain responses as measured by pain assessment score for continuous pain/stress (ALPS-Neo and Comfort Neo) in relation to PKFrom admission to the department until 4- 72 h after reaching normothermia.
Procedural pain response at a short standardized pain stimulation; as assessed with change in galvanic skin response, change in serum-cortisol and scored by a procedural pain assessment scale (PIPP-R) in relation to PK.Once during stable treatment with hypothermia and 6 hours of unchanged medication
Pharmacogenetic profile in relation to PK and PD results; how PK/PD phenotypes depend on pharmacogenetic (PG) profiles.One blood sample during study
Change in/association between physiological parameters (heart rate, blood pressure, peripheral oxygen saturation and NIRS (near-infrared reflectance spectroscopy near-infrared spectroscopy) parameters) in relation to PK parametersFrom admission to the department until 4- 72 h after reaching normothermia.

Trial Locations

Locations (2)

Skåne Uniersity Hospital

🇸🇪

Lund, Sweden

Karolinska University Hospital

🇸🇪

Stockholm, Sweden

© Copyright 2025. All Rights Reserved by MedPath